Acepodia Presents Preclinical Data on its Lead NK Cell Therapy Candidate ACE1702 at 2020 AACR Virtual Meeting II Preclinical data demonstrate anti-tumor activity with ACE1702 in vitro and in vivo  SAN FRANCISCO and TAIPEI, Taiwan, June 22, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing...

Acepodia Provides Corporate Update and Unveils New Preclinical Allogeneic NK Cell Therapy Pipeline Candidates at BIO Digital 2020 First clinical trial site for ACE1702 initiated, with clinical data expected in Q4 2020Investigational New Drug clearance expected for ACE1755 in Q1 2021 Pipeline expansion incorporating CAR...

Acepodia Announces FDA Clearance of IND for its NK Cell Therapy Drug Candidate ACE1702 to Treat Patients with HER2-expressing Solid Tumors SAN FRANCISCO and TAIPEI, Taiwan, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing cancer immunotherapy based on its novel ACC™ (Antibody Cell-Conjugation) technology...